Masotti A, Fumagalli L, Morandini G C
Division of Pneumology, Azienda Ospedaliera di Verona, Italy.
Monaldi Arch Chest Dis. 1997 Jun;52(3):225-8.
The aim of this study was to assess the feasibility and effectiveness of intrapleural administration of recombinant human interleukin-2 (rhIL-2) for treatment of malignant pleural effusions. From May 1993 to May 1995, 21 patients with non-small cell lung cancer (NSCLC) and cytologically documented malignant pleural effusion entered the study. After complete needle drainage of the effusion, a dose of 9 x 10(6) international units (IU) rhIL-2 was injected intracavitarily. The drug was injected on the first and second day each week for 3 weeks, in relation to the presence of effusion. Complete response (according to the criteria reported by Paladine st al.) was achieved in 7 of the 21 patients (33%), and partial response in 6 of the 21 patients (29%), with a median duration of 8 months (range 4-10 months). The treatment was well tolerated by all patients. Intracavitary administration of low-dose recombinant human interleukin-2 in malignant pleural effusion due to non-small cell lung cancer is an effective and well tolerated therapeutic strategy.
本研究的目的是评估胸腔内注射重组人白细胞介素-2（rhIL-2）治疗恶性胸腔积液的可行性和有效性。1993年5月至1995年5月，21例非小细胞肺癌（NSCLC）且经细胞学证实有恶性胸腔积液的患者进入本研究。在胸腔积液完全经针吸引流后，向胸腔内注射9×10⁶国际单位（IU）的rhIL-2。根据胸腔积液的情况，每周的第一天和第二天注射药物，共注射3周。21例患者中有7例（33%）达到完全缓解（根据Paladine等人报告的标准），21例患者中有6例（29%）达到部分缓解，中位缓解持续时间为8个月（范围4 - 10个月）。所有患者对该治疗耐受性良好。对于非小细胞肺癌所致恶性胸腔积液，胸腔内注射低剂量重组人白细胞介素-2是一种有效且耐受性良好的治疗策略。
